What do systematic reviews say?

First‐line thiazides vs calcium channel blockers

First‐line thiazides probably leads to lower total cardiovascular events Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 0.93 [0.89, 0.98]
  6 studies · 35217 participants
  Moderate

First‐line thiazides vs calcium channel blockers

First‐line thiazides showed no clear difference in total stroke Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 1.06 [0.95, 1.18]
  6 studies · 35217 participants
  Moderate

First‐line thiazides vs calcium channel blockers

First‐line thiazides showed no clear difference in total CHD Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 1 [0.93, 1.08]
  6 studies · 35217 participants
  Moderate

First‐line thiazides vs calcium channel blockers

First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 0.74 [0.66, 0.82]
  6 studies · 35217 participants
  Moderate

First‐line thiazides vs calcium channel blockers

First‐line thiazides may leads to lower withdrawals due to adverse effects Duration: 1 to 5 years compared with first‐line calcium channel blockers (low certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 0.81 [0.75, 0.88]
  7 studies · 33908 participants
  Low

First‐line thiazides vs calcium channel blockers

First‐line thiazides showed no clear difference in total mortality Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.96, 1.08]
  7 studies · 35417 participants
  Moderate

First‐line thiazides vs calcium channel blockers

First‐line thiazides showed no clear difference in total serious adverse events Duration: 1.75 to 3 years compared with first‐line calcium channel blockers (low certainty).

• First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
  RR 1.09 [0.97, 1.24]
  2 studies · 7204 participants
  Low

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aldosterone antagonists vs calcium channel blockers

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Aldosterone antagonists vs calcium channel blockers

The review found no eligible studies for this question.

• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Sevelamer vs calcium

Summary of findings: Sevelamer may leads to lower death (all causes) compared with calcium (low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.53 [0.3, 0.91]
  16 studies · 3688 participants
  Low

Summary of findings: Sevelamer vs calcium

It is very uncertain whether summary of findings: Sevelamer changes cardiovascular death compared with calcium (very low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.45 [0.11, 1.77]
  6 studies · 2829 participants
  Very low

Summary of findings: Sevelamer vs calcium

It is very uncertain whether summary of findings: Sevelamer changes hypercalcaemia compared with calcium (very low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.3 [0.2, 0.43]
  19 studies · 4084 participants
  Very low

Summary of findings: Sevelamer vs calcium

Summary of findings: Sevelamer showed no clear difference in nausea compared with calcium (low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.98 [0.56, 1.71]
  4 studies · 365 participants
  Low

Summary of findings: Sevelamer vs calcium

Summary of findings: Sevelamer showed no clear difference in vomiting compared with calcium (low certainty).

• Phosphate binders for preventing and treating chronic kidney disease‐mineral and bone disorder (CKD‐MBD) 2018 · Cochrane Headline outcomes only
  RR 0.95 [0.54, 1.69]
  2 studies · 263 participants
  Low